1252018-28-2 Usage
Description
(R)-4-(4-(5-(chloroMethyl)-2-oxooxazolidin-3-yl)phenyl)Morpholin-3-one, also known as TIC10, is a small molecule compound with potential anti-cancer properties. It has been shown to induce tumor cell death and inhibit tumor growth in various preclinical studies. TIC10 works by activating the tumor suppressor gene called TRAIL, which triggers a cascade of events leading to cancer cell death. Additionally, TIC10 has exhibited low toxicity in normal cells, making it a potentially promising therapeutic agent for cancer treatment.
Uses
Used in Pharmaceutical Industry:
(R)-4-(4-(5-(chloroMethyl)-2-oxooxazolidin-3-yl)phenyl)Morpholin-3-one is used as an anti-cancer agent for its ability to induce tumor cell death and inhibit tumor growth. It activates the tumor suppressor gene TRAIL, leading to a cascade of events that result in cancer cell death.
Used in Cancer Research:
(R)-4-(4-(5-(chloroMethyl)-2-oxooxazolidin-3-yl)phenyl)Morpholin-3-one is used as a research compound to study its potential applications in cancer therapy and to understand its mechanism of action. Further research and clinical studies are needed to fully comprehend its effectiveness and safety profile in treating various types of cancer.
Used in Drug Development:
(R)-4-(4-(5-(chloroMethyl)-2-oxooxazolidin-3-yl)phenyl)Morpholin-3-one is used as a lead compound in the development of new cancer therapeutics. Its low toxicity in normal cells and potential to activate the tumor suppressor gene TRAIL make it a promising candidate for the development of targeted cancer treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 1252018-28-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,2,0,1 and 8 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1252018-28:
(9*1)+(8*2)+(7*5)+(6*2)+(5*0)+(4*1)+(3*8)+(2*2)+(1*8)=112
112 % 10 = 2
So 1252018-28-2 is a valid CAS Registry Number.
1252018-28-2Relevant articles and documents
An approach to the anticoagulant agent rivaroxaban via an isocyanate-oxirane cycloaddition promoted by MgI2.etherate
Li, Chao,Liu, Yingshuai,Zhang, Yongjun,Zhang, Xingxian
, p. 400 - 401 (2011)
A convergent and efficient synthesis of anticoagulant rivaroxaban was developed using the cycloaddition of commercially available (R)-epichlorohydrin with 4-(morpholin-3-one)phenyl isocyanate catalysed by MgI2 etherate as the key step, in 22% overall yield.
PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS
-
, (2012/12/13)
The invention relates to a process for the preparation of 5-chloro- N- ({(5-S)-2-oxo3-[4-(3-oxo-morj)holine-4-yl)-phenyl]-l,3-oxazolidine-5-yl}-methyl) thiophen-2-carboxamide having the INN rivaroxaban. The process is characterized by the reactions according to claim 1. The invention also relates to intermediates formed in the above process.
